The next-generation antibody is intended to be more specific & more potent than the traditional monoclonal antibodies. Next-generation antibody therapeutics is used for the treatment of different medical conditions such as infectious diseases, cancer and autoimmune diseases to improve the current properties of therapeutic antibodies.
According to study, “Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030” the key companies operating in the global next-generation antibody therapeutics market are Amgen Inc., Kyowa Hakko Kirin Co. Ltd., AstraZeneca PLC., F. Hoffmann-La Roche Ltd., Bayer AG, Seattle Genetics Inc., Biogen, Takeda Pharmaceuticals Company Limited, Bristol-Myers Squibb Company, ImmunoGen Inc., Dyax Corp., Pfizer Inc. and Xencor Inc. The key companies have either set up their manufacturing services or are planning to start new stipulation in the dominated region in the upcoming years.
Based on type, next-generation antibody therapeutics market is segmented as Antibody Fragments and Antibody-Like Proteins (AF & ALPs), Antibody Drug Conjugates (ADCs), Fc Engineered Antibodies, Bispecific Antibodies (BsAbs) and Biosimilar Antibody (Ab) Products. The ADC technology consolidates the cytotoxic potential of chemotherapy and profitable characteristics of antibodies that prompts high specificity and efficiency of ADCs. Based on application, market is segmented as autoimmune/inflammatory and oncology. The oncology segment is predicted to witness higher growth rate due to rise in incidence of cancer during the forecast period. In addition, based on end-user, market is segmented as clinics, hospitals and others.
The next-generation antibody therapeutics market is driven by increase in prevalence of chronic diseases, followed by rise in number of collaborations for Research & Development (R&D) in next-generation antibody therapeutics, growth in production & invention of new medicines, and increase in applications of such therapies. However, stringent regulatory related to antibody therapeutics and lengthy approval processes and higher costs of therapeutics may impact the market. Moreover, growth in technological advancements in antibody therapeutics, rise in demand for better healthcare services and growth in biosimilar antibodies & engineered antibodies are key opportunities for market. Furthermore, increase in popularity of ADC technology is a key trend for market.
Based on geography, the North-American region holds major share in global next-generation antibody therapeutics market owing to increase in investment on R&D of the next generation antibody drugs by governments in the region. The European and Asian-Pacific regions are estimated to witness higher growth rate due to surge in the geriatric population, rise in healthcare expenditure coupled with increase in government initiatives over the forecast period. It is expected that future of the global market will be optimistic caused by increase in prevalence of chronic diseases and growth in improvement of life sciences research infrastructure during the forecast period. The global next-generation antibody therapeutics market is valued around at US $4.69 million in 2019 and is anticipated to grow at US $14.26 million by 2030, at a CAGR of 13.69% during the forecast period.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications